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Abstract Human epidermal growth factor receptor 2 (HER2)
status in breast carcinomas serves as a predictor of benefit
from anti-HER2 therapy. In providing clinicians with the in-
formation necessary to decide whether or not to treat with
targeted therapy, it might be necessary to choose between
methods assessing HER2 protein overexpression or gene am-
plification. A new diagnostic approach could be a combina-
tion of both tests on the same slide. If accurate and reproduc-
ible, this approach might optimize patient stratification for
therapy. In this study, formalin-fixed paraffin-embedded tu-
mor samples from 77 breast cancer patients were examined
for HER2 by immunohistochemistry (IHC) and silver in situ
hybridization (SISH) using HER2 IHC (clone 4B5),
HER2/CEN17SISH, and combined IHC and SISH assay,
called gene protein (GP). Cases were selected to ensure a
sufficient number of borderline cases on the basis of IHC
scores (0, 1+, 2+, 3+), obtained during diagnostic histopatho-
logical workup. The concordance between the HER2 IHC
score obtained during diagnostic histopathological workup
and GP was 93 %. Discordances had no influence on therapy
decisions. The concordance between ISH results using dual
ISH (DISH) and GP was 96%. Of the 77 cases studied by GP,
three cases with a ratio close to 2 would have been called
amplified by DISH. The use of GP reduced the time for slide
reading for a trained pathologist by up to 25 %, relative to
sequential reading of IHC followed by SISH. For cases with
an IHC score of 2+, the final result was obtained in 1 day,
while the sequential technique would have required retesting
by ISH on a second day. In conclusion, assessment of HER2
status by GP is an improvement for pathologists and facilitates
clinical decision-making for breast cancer management.
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Introduction
Human epidermal growth factor receptor 2 (HER2) is a pro-
tein on the surface of cancer cells that stimulates tumor
growth. When the HER2 gene is amplified, it triggers over-
production, commonly called overexpression, of HER2 [1]
protein. Tumors that strongly overexpress HER2 and/or those
with a proven amplification of theHER2 gene are classified as
being HER2 positive. HER2-positive cancers are associated
with poor overall prognosis with faster time to relapse or pro-
gression at all stages [2–4]. In the early days of HER2 testing,
amplification of the HER2 gene and the corresponding over-
expression of HER2 protein was found in approximately 25 to
30 % of breast cancer [5], but this rate was probably an over-
estimate as it is now identified in approximately 15 to 20% [6]
of primary breast cancer cases, while recent data show a fur-
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Assessment of HER2 status in the breast is required to
support treatment decisions, as it predicts response to HER2
targeted therapies. Presently, four HER2-targeted therapies are
approved by the Food and Drug Administration (FDA) for
treatment of HER2-positive breast cancer: Trastuzumab®,
Lapatinib®, Pertuzumab®, and Trastuzumab emtasine®. In ad-
dition, promising new approaches are being developed includ-
ing monoclonal antibodies and small-molecule tyrosine ki-
nase inhibitors targetingHER2 or other HER familymembers,
antibodies linked to cytotoxic moieties or modified to improve
their immunological function, immunostimulatory peptides,
and PI3K and IGF-1R pathway [8, 9] targets.
To date, only two techniques for HER2 status determina-
tion are validated, FDA approved, and broadly used in a di-
agnostic setting. Immunohistochemical (IHC) analysis iden-
tifies HER2 protein expression on the cell surface, while in
situ hybridization (ISH) determines the degree of HER2 gene
amplification. Both methods are highly specific and reproduc-
ible when performed under standardized and validated condi-
tions. HER2 testing has been standardized for breast carcino-
ma, and the American Society of Clinical Oncology (ASCO)
recommends that HER2 status should be determined for all
invasive breast cancers [10, 11]. The ASCO/CAP 2007 HER2
guidelines provide an algorithm defining positive and nega-
tive status for both HER2 protein expression and gene ampli-
fication. Cases demonstrating IHC staining of 3+ (uniform,
complete intense membranous staining of more than 30 % of
invasive tumor cells) or an ISH HER2 copy number ≥6 or a
ratio HER2 gene signal to chromosome 17 signal ≥2.2 are
considered positive. A negative result is IHC staining of 0 or
1+ or ISH HER2 copy number <4 or a ratio <1.8. The recently
revised ASCO-CAP 2003 guidelines state that all tumors with
complete, intense circumferential membrane staining of more
than 10%of the cells are considered as 3+ and therefore positive.
HER2 status by ISH is positive for cases showing a HER2
gene to chromosome 17 signal ratio ≥2, regardless of the
number of HER2 copies. Cases with a HER2 gene to chromo-
some 17 ratio <2 but with a HER2 copy number of 6 or higher
are also considered positive.
Cases with complete membrane staining, that is either non-
uniform or weak in intensity but with obvious circumferential
distribution in at least 10 % of cells (IHC 2+), are considered
equivocal and require assessment by ISH [19]. This group
accounts for approximately 15 % of all tumors and, for
optimal guidance of HER2 targeted therapy, further quan-
tification of gene copy number to determine amplification
status is needed [12]. In the revised version of the ASCO-
CAP guidelines, the definition of IHC equivocal cases
changed to tumors with circumferential membrane stain-
ing that is incomplete and/or weak/moderate in more than
10 % of tumors cells, or with intense complete circumfer-
ential membrane staining in less than or equal to 10 % of
the tumor cells.
For cases with an equivocal ISH ratio of 1.8-2.2, additional
cells should be scored to allow a diagnostic decision to be
reached. A ratio of 1.80-1.99 should be reported as borderline
not amplified and HER2 negative and a ratio of 2.00-2.20 as
borderline amplified and HER2 positive. It is recommended
that laboratories show at least 95% concordance between IHC
and ISH. The revised version of the ASCO-CAP guidelines
also changes the definition for equivocal cases defined by ISH
testing. Cases with an HER2 gene copy to chromosome 17
signal ratio above 2 or with an HER2 signal number between
4 and 6 are considered equivocal.
Based on the ASCO guidelines, the currently most widely
used testing algorithm for breast carcinoma consists of first-
line HER2 IHC staining followed by ISH testing for 2+ cases.
This algorithm may result in some discordant cases, e.g.,
IHC 0 or 1+ cases amplified in ISH or IHC 3+ cases
nonamplified in ISH, amounting to about 4 % of cases as
described by Lee et al. [13] and Bernasconi et al. [14]. In
addition, intratumor heterogeneity of HER2 gene amplifica-
tion has been observed in breast cancer, ranging from a few
[15] to up to 36 % of the amplified cases [16], which intro-
duces additional difficulties in HER2 status evaluation espe-
cially for equivocal cases [17]
The long history of HER2 testing in breast cancer is an
indication of the importance of continuing efforts to improve
HER2 diagnostic assays and their interpretation, to ensure that
patients whomay benefit receive the appropriate targeted ther-
apy. A new robust and reliable method, that would allow as-
sessment of protein expression and gene amplification status
on the same slide, could be a significant improvement. The
aim of this study is to test the feasibility and reliability of this




A new gene and protein detection platform (GP, Ventana)
combines IHC staining with ISH. To estimate HER2 GP reli-
ability, results were compared with FDA-approved INFORM
HER2 DISH DNA Probe Cocktail and HER2 IHC (clone
4B5) assays (Ventana).
Patients
Patients were selected based upon previously performed diag-
nostic IHC staining, with the intention to include a sufficient
number of borderline cases. This resulted in a case series of 10
cases without IHC overexpression (0), 18 with weak staining
(1+), 35 with moderate staining (2+), and 14 with strong
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staining (3+). For this study, HER2 IHC status of all cases was
confirmed by a second IHC analysis done in one staining run.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded sections were dried at
60 °C for 2 h and then processed on a BenchMark XT auto-
mated slide-stainer (Ventana). All used reagents were from
Ventana. After deparaffinization and pretreatment (Cell
Conditioning I for 30 min at 95 °C), sections were incubated
with primary antibody (clone 4B5) for 20 min at 37 °C and
secondary antibody (HRP-conjugated goat anti-rabbit anti-
body). Immunoreactivity was detected with the iView DAB
Detection Kit, and counterstaining was performed with
Hematoxylin II.
Dual color in situ hybridization
Formalin-fixed paraffin-embedded sections were dried at
60 °C for 2 h and then processed on a BenchMark XT auto-
mated slide-stainer (Ventana). All used reagents were from
Ventana. After deparaffinization and pretreatment (Cell
Conditioning II, protease, denaturation), sections were ex-
posed to probe hybridization (Chromosome 17 centromere
labeled with DIG and HER2 labeled with DNP) with
HybReady and stringency washing using SSC solution. The
DNP probe was detected with ultraView SISH DNP [black
dots] and the DIG probe with the ultraView Red [red dots],
and the slides were counterstained with hematoxylin.
HER2 gene and protein platform
Formalin-fixed paraffin-embedded sections were dried at
60 °C for 2 h and then processed on a BenchMark XT auto-
mated slide-stainer (Ventana). All used reagents were from
Ventana. The staining procedure in essence consisted of sub-
sequent application of the IHC and double ISH procedures as
described above. HybClear is a unique reagent specific to the
Ventana GP platform that enables combination of both tech-
niques on a single slide by blocking silver dust background.
The total duration of the protocol was about 15 h.
Scoring of staining results
IHC and ISH results were scored by an experienced breast
pathologist (MPC) only in invasive carcinoma, by bright field
microscopy using ×20, ×40, and ×60 objectives. IHC staining
results were classified according to ASCO-CAP 2007 guide-
lines taking into account staining intensity, localization, and
extent (% of positive staining cells) into 0, 1+, 2+, and 3+
groups. ISH signals were reported as single copies, multiple
copies, and clusters. Normal HER2 or CEN17 signals (one to
two copies/cell in stromal fibroblasts, endothelial cells,
lymphocytes, and benign breast epithelial cells) served as in-
ternal positive control, which was considered as adequate
when the signals were visible in the sample at any magnifica-
tion used. Aminimum of 10 cells were scored in cases without
variation between nuclei or clustered signals, and 20 to 40
cells were scored for cases with 2+ IHC and/or internuclear
variation. The number of HER2 signals was divided by the
number of CEN17 signals to obtain a HER2/CEN17 ratio.
GP-stained slides were first evaluated at low power to score
HER2 expression, as performed for only IHC-stained slides.
An ISH score was then established at higher magnification.
Slides were read in a randomized manner by session of 45
slides (15 IHC, 15 ISH, and 15 GP slides). To avoid influence
of previously seen slides on scoring, within a reading session
IHC, ISH, and GP were independently scored and subsequent
sessions never concerned the same 15 cases. The duration of




Single IHC staining was successful on all cases. Dual SISH
was successful initially on 69 cases and with an additional
staining run on 3 more cases. GP staining was successful on
74 cases after the first run and on 3 more cases with a second
run. This left 72 cases for which results of the 3 staining
procedures were available.
The first impression when looking at GP-stained slides was
that immunostaining is less crisp, which might be due to the
pretreatment required for the DISH step. However, this had no
impact on reading or scoring, following ASCO-CAP 2007 or
the recently published ASCO-CAP 2013 guidelines, although
reading GP-stained slides might require some time for an ex-
perienced pathologist to adapt (Fig. 1). The quality of DISH
staining obtained with GP was judged as good as the with
DISH staining only. In some HER2 3+ cases, DISH staining
resulted in smaller dots or clusters, or areas of strong mem-
branous DAB staining without ISH signals. In these cases,
IHC 3+ score and/or an HER2/CEN17 ratio of 2 (or more than
five copies of HER2) in other areas allowed valid HER2 status
assessment (Fig. 1).
Concordance of IHC on single and GP-stained slides
The concordance between HER2 expression using IHC only
and GP was 93 % (Table 1). Minor discrepancies were ob-
served for 1+ cases, without any impact on HER2 status
assessment.
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Concordance of ISH on DISH and GP-stained slides
The concordance between the HER2/CEN17 ratios obtained
onDISH andGP-stained slides was 94% (96%when reduced
to amplified or not amplified status, Tables 2 and 3). In three
cases, DISH and GP results were discrepant. These were
borderline cases, corresponding to those reported in the liter-
ature with interobserver and intraobserver variability
(HER2/CEN17 between 1.8 and 2.2).
Concordance of HER2 status on IHC + ISH
and GP-stained slides
Using the previously described algorithm (first HER2 IHC
and DISH only for 2+ cases), with one exception all cases
were concordant (Table 4). The discordant case was scored
as 0 by IHC in single staining IHC and GP but ISH amplified
by both DISH and GP staining (mean HER2 copy number >6,
HER2/CEN17 <2 due to polysomy) (Fig. 2), even though
close to the cutoff value (6.5 for DISH and 6.05 for GP).
Reading time comparing IHC + ISH with GP
The regression curve comparing reading time to result of IHC
followed by DISH with GP showed y=0.7355, corresponding
to a gain in time of reading of 25%, notably when focusing on
borderline (1+ and 2+ IHC) cases (data not shown).
Discussion
In this study, we tested a new technique for simultaneous
assessment of HER2 protein expression and gene amplifica-
tion status. This technique was first described by Nitta et al.
[18] and Hierschmann et al. [19] and optimizes determination
of HER2 status as well as allowing identification of cases in
which HER2 IHC and HER2 ISH statuses are not concordant.
Although breast cancer heterogeneity has been described as a
major cause of variability in the assessment of HER2 status,
this was not the focus of our study. The possibility to observe
simultaneously HER2 expression and HER2 amplification
will guide the observer to the most relevant tumor area and
Fig. 1 IHC (a), DISH (b), and GP (c) staining of the same breast
carcinoma case at ×40. HER2 IHC score is determined as 3+ for both
IHC and GP, with similar staining pattern and intensity. Similar
amplification with clusters is observed in both DISH and GP techniques
Table 1 Comparison of
HER2 IHC score
determined on IHC and
GP slides
IHC
0 1+ 2+ 3+
GP 0 7 4 0 0
1+ 1 11 0 0
2+ 0 0 36 0
3+ 0 0 0 13
Table 2 Comparison of
HER2 IHC score
determined on IHC and
GP slides classified as
NEG (negative) for 0 and
1+ and POS (positive) as
2+ and 3+ cases
IHC
NEG POS
GP NEG 23 0
POS 0 49
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also show areas in which HER2 amplification is not accom-
panied by protein overexpression. Such differences might be
related to preanalytical parameters or to as-yet unidentified
biological events [20] .
Although IHC and ISH are robust and reliable techniques,
misclassification does occur following the ASCO-CAP test-
ing algorithm [14], which might incur changes in patient treat-
ment. Only patients with a positive HER2 status, either HER2
IHC 3+ or amplified, will be treated with one of the anti HER2
therapies [23–27]. In our study, one case did not show over-
expression (scored as 0 both in IHC only and GP) but was
amplified (in both techniques, Fig. 2). This case would have
been classified as negative using the ASCO-CAP testing al-
gorithm. However, as the case showedmore than six copies of
HER2 a l t h o u g h i t w a s p o l y s om i c ( r a t i o o f
HER2/Chromosome 17 below 2), following the same
ASCO-CAP rules this patient qualifies for treatment with
targeted anti-HER2 therapy.
We found the GP assay more robust than the DISH assay.
After GP staining, 96 % of the slides could be scored while
this was the case for only 90 % of the DISH-stained slides.
This may be due to the stronger pretreatment necessary in GP
staining as it consists of successive pretreatments for IHC and
for DISH (the latter being similar to DISH only but longer and
with a higher protease concentration).
In our institution, the workflow for HER2 testing of IHC
2+ cases requires up to 3 days because of the need for addi-
tional ISH testing. This is acceptable but may become prob-
lematic when due to technical failure a second staining round
would be required especially for ISH, as in such event a final
result for HER2 status assessment might take up to 1 week.
Using GP, complete HER2 status can be determined in 1 day,
or 2 days if the staining is done overnight. Moreover, although
the success rate of GP is not perfect, it was better than ISH
alone, with only three cases that could not be interpreted after
a single staining round. Workflow is also positively affected
Table 3 Comparison of HER2 ISH score determined on DISH and GP
slides classified as NEG (negative) when case show a ratio
HER2/Chromosome 17 below 2 and less than six copies and POS
(positive) when the case show a ratio above 2 or a mean copy number
of HER2 gene above or equal 6
DISH
Neg Pos
GP Neg 46 2
Pos 1 23







GP Neg 48 0
Pos 1 23
Positive and negative cases are defined ac-
cording to ASCO-CAP guidelines
Fig. 2 IHC (a), DISH (b), and GP (c) staining of the same breast
carcinoma case at ×40. HER2 IHC score is determined as 0 for both
IHC and GP, with similar staining pattern and intensity (faint
cytoplasmic). Low level amplification was detected (≥6 copies, ratio
above 2 due to minor polysomy) in both DISH and GP slides. This case
would not have been eligible for HER2-targeted therapy using IHC alone
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by the use of only a single slide. However, the cost of the GP
test is higher than that of the two separate IHC and DISH tests,
and therefore, assessment of cost-effectiveness should be con-
ducted to arrive at a comprehensive cost-benefit analysis in
terms of treatment optimization [21, 22] .
For borderline cases, we observed that GP reduced the time
to get to a final result by 25 %. The reading time required for
evaluation of 0 and 3+ cases is not changed in the GP assay, as
HER2 protein expression of these cases will be read at low
magnification. However, evaluating protein expression and
gene amplification in the same slide allows the pathologist
to avoid false negative such as in our case with HER2 IHC
0 but HER2 amplification.
The number of tests required to arrive at a final diagnosis
increases constantly and will continue to do so in the coming
years with new targeted therapies coming along. More tests
will require more biological materials, while at the same time
clinicians attempt to decrease invasive diagnostic procedures
such as surgery or biopsy, which confronts pathologists with
reduced sample size. Sample size may become too low to do
all required tests with traditional approaches. Consequently,
combined testing will be increasingly important to get as
much information as possible from little material. GP com-
bines assessment of gene amplification with that of protein
expression and provides an elegant option for assessment of
HER2 status in breast cancer. As a generic detection method,
GP is not limited to one biomarker and provides an opportu-
nity for exploring other marker tests in other diseases.
In conclusion, the combined GP assay improves laboratory
workflow and improves patient management by delivering
more precise and faster results. A final result for HER2 2+
cases can be delivered within 1 day, while sequential staining
requires at least a second day to perform subsequent SISH
testing. Efficacy could be further increased by a higher suc-
cess rate, which needs to be confirmed in further studies.
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